Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Gynecology

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 65 articles:
HTML format
Text format



Single Articles


    September 2019
  1. ZHAO J, Giri A, Zhu X, Shrubsole MJ, et al
    Calcium: magnesium intake ratio and colorectal carcinogenesis, results from the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2019 Sep 23. pii: 10.1038/s41416-019-0579.
    PubMed     Text format     Abstract available


  2. COLOMBO N, Zaccarelli E, Baldoni A, Frezzini S, et al
    Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.
    Br J Cancer. 2019 Sep 20. pii: 10.1038/s41416-019-0584.
    PubMed     Text format     Abstract available


    August 2019
  3. TASSI RA, Gambino A, Ardighieri L, Bignotti E, et al
    FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.
    Br J Cancer. 2019 Aug 22. pii: 10.1038/s41416-019-0553.
    PubMed     Text format     Abstract available


  4. LECAVALIER-BARSOUM M, Chaudary N, Han K, Pintilie M, et al
    Correction: Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy.
    Br J Cancer. 2019 Aug 9. pii: 10.1038/s41416-019-0545.
    PubMed     Text format     Abstract available


  5. RUSSELL MR, Graham C, D'Amato A, Gentry-Maharaj A, et al
    Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel.
    Br J Cancer. 2019 Aug 7. pii: 10.1038/s41416-019-0544.
    PubMed     Text format     Abstract available


  6. SHI T, Jiang R, Pu H, Yang H, et al
    Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study.
    Br J Cancer. 2019 Aug 6. pii: 10.1038/s41416-019-0543.
    PubMed     Text format     Abstract available


    June 2019
  7. LECAVALIER-BARSOUM M, Chaudary N, Han K, Pintilie M, et al
    Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy.
    Br J Cancer. 2019 Jun 26. pii: 10.1038/s41416-019-0497.
    PubMed     Text format     Abstract available


  8. QIAN F, Rookus MA, Leslie G, Risch HA, et al
    Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers.
    Br J Cancer. 2019 Jun 19. pii: 10.1038/s41416-019-0492.
    PubMed     Text format     Abstract available


  9. PLUMMER C, Michael A, Shaikh G, Stewart M, et al
    Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK.
    Br J Cancer. 2019 Jun 11. pii: 10.1038/s41416-019-0481.
    PubMed     Text format     Abstract available


    April 2019
  10. REIJNEN C, van Weelden WJ, Arts MSJP, Peters JP, et al
    Poor outcome in hypoxic endometrial carcinoma is related to vascular density.
    Br J Cancer. 2019 Apr 23. pii: 10.1038/s41416-019-0461.
    PubMed     Text format     Abstract available


  11. HORN J, Denecke A, Luyten A, Rothe B, et al
    Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany.
    Br J Cancer. 2019 Apr 16. pii: 10.1038/s41416-019-0453.
    PubMed     Text format     Abstract available


    March 2019
  12. FORTNER RT, Terry KL, Bender N, Brenner N, et al
    Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses' Health Studies.
    Br J Cancer. 2019 Mar 21. pii: 10.1038/s41416-019-0422.
    PubMed     Text format     Abstract available


  13. WESTERGAARD MCW, Andersen R, Chong C, Kjeldsen JW, et al
    Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.
    Br J Cancer. 2019 Mar 19. pii: 10.1038/s41416-019-0425.
    PubMed     Text format     Abstract available


  14. GORANOVA T, Ennis D, Piskorz AM, Macintyre G, et al
    Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.
    Br J Cancer. 2019 Mar 13. pii: 10.1038/s41416-019-0433.
    PubMed     Text format     Abstract available


    February 2019
  15. FROELING FEM, Ramaswami R, Papanastasopoulos P, Kaur B, et al
    Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours.
    Br J Cancer. 2019 Feb 22. pii: 10.1038/s41416-019-0402.
    PubMed     Text format     Abstract available


  16. WESTERGAARD MCW, Andersen R, Chong C, Kjeldsen JW, et al
    Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.
    Br J Cancer. 2019 Feb 5. pii: 10.1038/s41416-019-0384.
    PubMed     Text format     Abstract available


    January 2019
  17. LEE CK, Scott C, Lindeman GJ, Hamilton A, et al
    Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
    Br J Cancer. 2019 Jan 17. pii: 10.1038/s41416-018-0349.
    PubMed     Text format     Abstract available


  18. MULATI K, Hamanishi J, Matsumura N, Chamoto K, et al
    VISTA expressed in tumour cells regulates T cell function.
    Br J Cancer. 2019;120:115-127.
    PubMed     Text format     Abstract available


    December 2018
  19. SINGEL KL, Grzankowski KS, Khan ANMNH, Grimm MJ, et al
    Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer.
    Br J Cancer. 2018 Dec 6. pii: 10.1038/s41416-018-0339.
    PubMed     Text format     Abstract available


    November 2018
  20. GILBERT DC, Wakeham K, Langley RE, Vale CL, et al
    Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis.
    Br J Cancer. 2018 Nov 28. pii: 10.1038/s41416-018-0273.
    PubMed     Text format     Abstract available


  21. GIANNAKEAS V, Cadarette SM, Ban JK, Lipscombe L, et al
    Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study.
    Br J Cancer. 2018 Nov 13. pii: 10.1038/s41416-018-0225.
    PubMed     Text format     Abstract available


    October 2018
  22. WORTMAN BG, Creutzberg CL, Putter H, Jurgenliemk-Schulz IM, et al
    Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.
    Br J Cancer. 2018 Oct 25. pii: 10.1038/s41416-018-0310.
    PubMed     Text format     Abstract available


  23. FRIEDLANDER M, Matulonis U, Gourley C, du Bois A, et al
    Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0271.
    PubMed     Text format     Abstract available


  24. HODGSON DR, Dougherty BA, Lai Z, Fielding A, et al
    Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0274.
    PubMed     Text format     Abstract available


  25. ARROYO-MUHR LS, Lagheden C, Hultin E, Eklund C, et al
    Human papillomavirus type 16 genomic variation in women with subsequent in situ or invasive cervical cancer: prospective population-based study.
    Br J Cancer. 2018 Oct 22. pii: 10.1038/s41416-018-0311.
    PubMed     Text format     Abstract available


  26. PATEL JN, Braicu I, Timms KM, Solimeno C, et al
    Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0268.
    PubMed     Text format     Abstract available


  27. NIEMI RJ, Braicu EI, Kulbe H, Koistinen KM, et al
    Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism.
    Br J Cancer. 2018 Oct 8. pii: 10.1038/s41416-018-0270.
    PubMed     Text format     Abstract available


  28. WANG P, Magdolen V, Seidl C, Dorn J, et al
    Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0260.
    PubMed     Text format     Abstract available


  29. WILLIAMS LA, Mills L, Hooten AJ, Langer E, et al
    Differences in DNA methylation profiles by histologic subtype of paediatric germ cell tumours: a report from the Children's Oncology Group.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0277.
    PubMed     Text format     Abstract available


    August 2018
  30. TSIBULAK I, Wieser V, Degasper C, Shivalingaiah G, et al
    BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
    Br J Cancer. 2018 Aug 15. pii: 10.1038/s41416-018-0217.
    PubMed     Text format     Abstract available


  31. AOKI Y, Ochiai K, Lim S, Aoki D, et al
    Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer.
    Br J Cancer. 2018 Aug 3. pii: 10.1038/s41416-018-0206.
    PubMed     Text format     Abstract available


    July 2018
  32. GADDUCCI A, Grosso F, Scambia G, Raspagliesi F, et al
    A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma.
    Br J Cancer. 2018 Jul 30. pii: 10.1038/s41416-018-0190.
    PubMed     Text format     Abstract available


  33. CARTER JH, Deddens JA, Mueller G, Lewis TG, et al
    Transcription factors WT1 and p53 combined: a prognostic biomarker in ovarian cancer.
    Br J Cancer. 2018 Jul 30. pii: 10.1038/s41416-018-0191.
    PubMed     Text format     Abstract available


  34. KOMMOSS FK, Karnezis AN, Kommoss F, Talhouk A, et al
    L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile.
    Br J Cancer. 2018 Jul 27. pii: 10.1038/s41416-018-0187.
    PubMed     Text format     Abstract available


  35. GHAFFARI A, Peterson N, Khalaj K, Vitkin N, et al
    STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer.
    Br J Cancer. 2018 Jul 26. pii: 10.1038/s41416-018-0188.
    PubMed     Text format     Abstract available


  36. HILLIARD C
    Comment on 'Dairy, calcium, vitamin D, and ovarian cancer risk in African-American women'.
    Br J Cancer. 2018 Jul 2. pii: 10.1038/s41416-018-0166.
    PubMed     Text format    


  37. QIN B, Peres LC, Schildkraut JM, Bandera EV, et al
    Reply to 'Comment on 'Dairy, calcium, vitamin D and ovarian cancer risk in African-American women''.
    Br J Cancer. 2018 Jul 2. pii: 10.1038/s41416-018-0163.
    PubMed     Text format    


    June 2018
  38. RUSCITO I, Cacsire Castillo-Tong D, Vergote I, Ignat I, et al
    Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
    Br J Cancer. 2018 Jun 29. pii: 10.1038/s41416-018-0157.
    PubMed     Text format     Abstract available


  39. SHI T, Jiang R, Yu J, Yang H, et al
    Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial.
    Br J Cancer. 2018 Jun 14. pii: 10.1038/s41416-018-0036.
    PubMed     Text format     Abstract available


  40. VIALATTE DE PEMILLE C, Berzero G, Small M, Psimaras D, et al
    Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies.
    Br J Cancer. 2018 Jun 14. pii: 10.1038/s41416-018-0125.
    PubMed     Text format     Abstract available


  41. ZHENG R, Du M, Zhang B, Xin J, et al
    Body mass index (BMI) trajectories and risk of colorectal cancer in the PLCO cohort.
    Br J Cancer. 2018 Jun 6. pii: 10.1038/s41416-018-0121.
    PubMed     Text format     Abstract available


  42. TUNG NM, Garber JE
    BRCA1/2 testing: therapeutic implications for breast cancer management.
    Br J Cancer. 2018 Jun 5. pii: 10.1038/s41416-018-0127.
    PubMed     Text format     Abstract available


    May 2018
  43. NEUMEYER S, Banbury BL, Arndt V, Berndt SI, et al
    Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer.
    Br J Cancer. 2018 May 24. pii: 10.1038/s41416-018-0108.
    PubMed     Text format     Abstract available


  44. DERKS-SMEETS IAP, Schrijver LH, de Die-Smulders CEM, Tjan-Heijnen VCG, et al
    Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers.
    Br J Cancer. 2018 May 1. pii: 10.1038/s41416-018-0139.
    PubMed     Text format     Abstract available


    March 2018
  45. LAGHEDEN C, Eklund C, Lamin H, Kleppe SN, et al
    Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer.
    Br J Cancer. 2018 Mar 21. pii: 10.1038/s41416-018-0053.
    PubMed     Text format     Abstract available


  46. DIXON-SUEN SC, Nagle CM, Thrift AP, Pharoah PDP, et al
    Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study.
    Br J Cancer. 2018 Mar 20. pii: 10.1038/s41416-018-0011.
    PubMed     Text format     Abstract available


  47. DI GIROLAMO C, Walters S, Gildea C, Benitez Majano S, et al
    Which patients are not included in the English Cancer Waiting Times monitoring dataset, 2009-2013? Implications for use of the data in research.
    Br J Cancer. 2018;118:733-737.
    PubMed     Text format     Abstract available


    February 2018
  48. GUSTAVSSON I, Aarnio R, Berggrund M, Hedlund-Lindberg J, et al
    Randomised study shows that repeated self-sampling and HPV test has more than two-fold higher detection rate of women with CIN2+ histology than Pap smear cytology.
    Br J Cancer. 2018 Feb 13. pii: bjc2017485. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  49. YUZHALIN AE, Urbonas T, Silva MA, Muschel RJ, et al
    A core matrisome gene signature predicts cancer outcome.
    Br J Cancer. 2018;118:435-440.
    PubMed     Text format     Abstract available


    January 2018
  50. GOEDERT JJ, Hua X, Bielecka A, Okayasu I, et al
    Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota.
    Br J Cancer. 2018 Jan 23. pii: bjc2017435. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  51. VERDOODT F, Kjaer SK, Dehlendorff C, Friis S, et al
    Aspirin use and ovarian cancer mortality in a Danish nationwide cohort study.
    Br J Cancer. 2018 Jan 9. pii: bjc2017449. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  52. LAM JUH, Elfstrom KM, Ejegod DM, Pedersen H, et al
    High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders.
    Br J Cancer. 2018;118:138-144.
    PubMed     Text format     Abstract available


    December 2017
  53. PLAYDON MC, Coburn SB, Moore SC, Brinton LA, et al
    Alcohol and oestrogen metabolites in postmenopausal women in the Women's Health Initiative Observational Study.
    Br J Cancer. 2017 Dec 12. pii: bjc2017419. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    November 2017
  54. SEAMON LG, Java JJ, Monk BJ, Penson RT, et al
    Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study.
    Br J Cancer. 2017 Nov 28. pii: bjc2017400. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  55. HALLE MK, Tangen IL, Berg HF, Hoivik EA, et al
    HER2 expression patterns in paired primary and metastatic endometrial cancer lesions.
    Br J Cancer. 2017 Nov 23. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  56. KAWAKITA D, Lee YA, Gren LH, Buys SS, et al
    The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort.
    Br J Cancer. 2017 Nov 21. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  57. MARKOVINA S, Wang S, Henke LE, Luke CJ, et al
    Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer.
    Br J Cancer. 2017 Nov 7. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    October 2017
  58. HEINONEN HR, Mehine M, Makinen N, Pasanen A, et al
    Global metabolomic profiling of uterine leiomyomas.
    Br J Cancer. 2017 Oct 26. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  59. POYNTER JN, Richardson M, Roesler M, Krailo M, et al
    Family history of cancer in children and adolescents with germ cell tumours: a report from the Children's Oncology Group.
    Br J Cancer. 2017 Oct 24. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    September 2017
  60. GAYARRE J, Martin-Gimeno P, Osorio A, Paumard B, et al
    Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
    Br J Cancer. 2017;117:1048-1062.
    PubMed     Text format     Abstract available


  61. WANG X, Zhu Q, Lin Y, Wu L, et al
    Crosstalk between TEMs and endothelial cells modulates angiogenesis and metastasis via IGF1-IGF1R signalling in epithelial ovarian cancer.
    Br J Cancer. 2017 Sep 12. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  62. POLMAN NJ, Veldhuijzen NJ, Heideman DAM, Snijders PJF, et al
    HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test.
    Br J Cancer. 2017 Sep 7. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    August 2017
  63. CALLAHAN CL, Schwartz K, Ruterbusch JJ, Shuch B, et al
    Leukocyte telomere length and renal cell carcinoma survival in two studies.
    Br J Cancer. 2017;117:752-755.
    PubMed     Text format     Abstract available


  64. BELGIOVINE C, Bello E, Liguori M, Craparotta I, et al
    Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
    Br J Cancer. 2017;117:628-638.
    PubMed     Text format     Abstract available


  65. BURGER EA, Pedersen K, Sy S, Kristiansen IS, et al
    Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway.
    Br J Cancer. 2017 Aug 3. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: